X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: Another example of the competitive market at work in Part D

By Nicole Longo  |    April 17, 2017
Hepatitis C is a devastating viral disease that can result in life-threatening and costly complications. Five years ago, the only available treatment for the disease often resulted in debilitating...   Read More

Medicare Monday: What they are saying about MedPAC’s Part B recommendations

By Nicole Longo  |    April 10, 2017
Last week, the Medicare Payment Advisory Commission (MedPAC) voted on a number of recommendations affecting Medicare Part B. These proposed changes could negatively impact patients’ access to Part...   Read More

Medicare Monday: A guide to MedPAC’s Part B vote this week

By Allyson Funk  |    April 3, 2017
The Medicare Payment Advisory Commission (MedPAC) is an independent congressional agency that advises Congress on issues related to the Medicare program, including payment, access to and quality...   Read More

Medicare Monday: A discussion on affordability and access to medicines

By Nicole Longo  |    March 27, 2017
In case you missed it, the American Society on Aging held its annual conference last week in Chicago, IL, where Lori Reilly, PhRMA executive vice president of policy, research & membership, spoke...   Read More

Medicare Monday: Billing code basics for biologics in Part B

By Allyson Funk  |    March 20, 2017
We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before. Today, we’re exploring how proposals from MedPAC would...   Read More

Medicare Monday: A closer look at Part B spending

By Nicole Longo  |    March 13, 2017
Earlier this month, MedPAC discussed Part B drug spending growth but neglected to put this information in the context of overall program spending. Spending on Part B medicines continues to be a...   Read More

Medicare Monday: New study further confirms increased use of generics after Part D

By Nicole Longo  |    March 6, 2017
On Medicare Monday, we’ve talked a lot about how things have changed since 2006 and the implementation of Part D. We’ve looked at how Part D costs less than originally projected, how premiums have...   Read More

Medicare Monday: There’s an agency called MedPAC?

By Nicole Longo  |    February 27, 2017
Now that we’ve learned more about IPAB and CMMI, there’s one more agency on our list to read up on this month – the Medicare Payment Advisory Commission (MedPAC).   Read More

Medicare Monday: Have you heard of CMMI?

By Nicole Longo  |    February 20, 2017
There are a number of acronyms commonly used in the health care world, which can often be confusing and complicated, so this week we’re tackling one of them: CMMI.   Read More

Medicare Monday: What is IPAB, and why is it bad for patients?

By Nicole Longo  |    February 13, 2017
In 2017, the Independent Payment Advisory Board (IPAB)couldfinally go into effect and come between patients and their health care providers. This week, we’re looking into this dangerous body.     Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates